Entries |
Document | Title | Date |
20080227195 | Expanding the eukaryotic genetic code - This invention provides compositions and methods for producing translational components that expand the number of genetically encoded amino acids in eukaryotic cells. The components include orthogonal tRNAs, orthogonal aminoacyl-tRNA synthetases, orthogonal pairs of tRNAs/synthetases and unnatural amino acids. Proteins and methods of producing proteins with unnatural amino acids in eukaryotic cells are also provided. | 09-18-2008 |
20080233639 | Fusion protein delivery system and uses thereof - The present invention provides a composition of matter, comprising: DNA encoding a viral Vpx protein fused to DNA encoding a protein. In another embodiment of the present invention, there is provided a composition of matter comprising: DNA encoding a viral Vpr protein fused to DNA encoding a protein. The present invention further provides DNA, vectors and methods for expressing a lentiviral pol gene in trans, independent of the lentiviral gag-pol. A gene transduction element is optionally delivered to a lentiviral vector according to the present invention. Also provided are various methods of delivering a virus inhibitory molecule to a target in an animal. Further provided is a pharmaceutical composition. | 09-25-2008 |
20080261302 | Methods of diagnosing or treating neurological diseases and cell degeneration - The invention discloses an isolated nucleic acid molecule encoding a protein molecule, the function of which is to protect cells against degeneration and/or cell death, wherein the amino acid sequence of the protein comprises the sequence shown in SEQ ID NO. 2 or a functional variant thereof. | 10-23-2008 |
20080299653 | ESTABLISHED CELL LINES FROM LYMANTRIA XYLINA - The present invention relates to | 12-04-2008 |
20090017535 | MODIFIED GREEN FLUORESCENT PROTEINS AND METHODS FOR USING SAME - The present invention provides nucleic acid molecules encoding mutant fluorescent proteins as well as proteins encoded by these nucleic acids. In addition, host-cells, stable cell lines and transgenic organisms comprising the above-referenced nucleic acid molecules are provided. The subject protein and nucleic acid compositions find use in a variety of different applications and methods, particularly for labeling of biomolecules, cells, or cell organelles. | 01-15-2009 |
20090047736 | Human T1R2 nucleic acid sequences and polypeptides - Binding assays for identifying compounds that modulate human T1R2 polypeptide associated taste are disclosed. These assays detect the specific binding of compounds to a human T1R2 polypeptide or the modulation of the specific binding of a compound that specifically binds to a human T1R2 polypeptide. The binding assays may include the use of detectable labels, e.g., radionuclides, enzymes, fluorophases, and the like. Compounds identified in these binding assays have putative application as T1R2 taste modulators, particularly sweet taste, and potentially are useful additives in compositions for human or animal consumption. | 02-19-2009 |
20090068733 | T2R, a novel family of taste receptors - The invention provides isolated nucleic acid and amino acid sequences of taste cell specific G-protein coupled receptors, antibodies to such receptors, methods of detecting such nucleic acids and receptors, and methods of screening for modulators of taste cell specific G-protein coupled receptors. | 03-12-2009 |
20090075372 | OBTENTION OF FOOD- OR AUTO-ANTIGEN SPECIFIC TR1 CELLS FROM A LEUKOCYTE OR PBMC POPULATION - An in vitro method for the obtention of a food- or auto-antigen specific Tr1 cell population from a leukocyte or a PBMC population, includes stimulating the PBMC or leukocyte population with the food- or auto-antigen, and recovering the food- or auto-antigen specific Tr1 cell population from the stimulated cell population. Preferably, the PBMC or leukocyte population is re-stimulated at least once with the same antigen after step (1), in the presence of IL-2 and at least one interleukin selected from the group consisting of IL-4 and IL-13. The in vitro method may further include a third step of expanding the recovered antigen-specific Tr1 cell population, advantageously by contacting them with feeder cells capable of expressing factors necessary for the expansion. Preferably, the feeder cells are recombinant insect feeder cells. | 03-19-2009 |
20090093051 | T1R1 Nucleic Acid Sequences and Vectors Containing Same - Newly identified mammalian taste-cell-specific G protein-coupled receptors, and the genes and cDNA encoding said receptors are described. Specifically, T1R G protein-coupled receptors active in taste signaling, and the genes and cDNA encoding the same, are described, along with methods for isolating such genes and for isolating and expressing such receptors. Methods for representing taste perception of a particular tastant in a mammal are also described, as are methods for generating novel molecules or combinations of molecules that elicit a predetermined taste perception in a mammal, and methods for simulating one or more tastes. Further, methods for stimulating or blocking taste perception in a mammal are also disclosed. | 04-09-2009 |
20090098649 | NEWLY ESTABLISHED CELL LINES FROM MARUCA VITRATA - The present invention relates to | 04-16-2009 |
20090104693 | UDP-GALACTOSE:BETA-DGALACTOSE-R4-ALPHA-D-GALACTOSYLTRANSFERASE, ALPHA4GAL-T1 - A novel gene defining a novel enzyme UDP-galactose: β-D-galactose-R 4-α-D-galactosyltransferase, termed α4Gal-T1, with unique enzymatic properties is disclosed. The invention provides isolated DNA molecules and DNA constructs encoding α4Gal-T1 and derivatives thereof by way of amino acid deletion, substitution or insertion exhibiting α4Gal-T1 activity, as well as cloning and expression vectors including such DNA, host cells comprising DNA encoding α4Gal-T1, and recombinant methods for providing α4Gal-T1. The enzyme α4Gal-T1 and α4Gal-active derivatives thereof are disclosed. Further, the invention discloses methods of obtaining α1, 4galactosyl glycosylated glycosphingolipids by use of an enzymatically active α4Gal-T1 protein thereof or by using cells stably transfected with a vector including DNA encoding an enzymatically active α4Gal-T1 protein as an expression system for recombinant production of such glycosphingolipids. Also a method for the identification of DNA sequence variations in the α4Gal-T1-coding exon by PCR, and detecting the presence of DNA sequence variation, are disclosed. | 04-23-2009 |
20090124004 | Insect desiccation resistance genes and uses thereof - An objective of the present invention is to provide polynucleotides encoding insect desiccation resistance proteins, and uses thereof. cDNA libraries were produced from | 05-14-2009 |
20090155899 | Modified Chimeric Polypeptides with Improved Pharmacokinetic Properties - Modified chimeric polypeptides with improved pharmacokinetics are disclosed. Specifically, modified chimeric Flt1 receptor polypeptides that have been modified in such a way as to improve their pharmacokinetic profile are disclosed. Also disclosed are methods of making and using the modified polypeptides including but not limited to using the modified polypeptides to decrease or inhibit plasma leakage and/or vascular permeability in a mammal. | 06-18-2009 |
20090170192 | METHODS AND DNA CONSTRUCTS FOR HIGH YIELD PRODUCTION OF POLYPEPTIDES - The invention provides an inclusion body fusion partner to increase peptide and polypeptide production in a cell. | 07-02-2009 |
20090221067 | Cell lines that express hetero oligomeric taste receptors - The present invention relates to the discovery that the T1R receptors assemble to form functional taste receptors. Particularly, it has been discovered that co-expression of T1R1 and T1R3 results in a taste receptor that responds to umami taste stimuli, including monosodium glutamate. Also, it has been discovered that co-expression of the T1R2 and T1R3 receptors results in a taste receptor that responds to sweet taste stimuli including naturally occurring and artificial sweeteners. Also the present invention relates to the use of hetero-oligomeric taste receptors comprising T1R1/T1R3 and T1R2/T1R3 in assays to identify compounds that respectively respond to umami taste stimuli and sweet taste stimuli. Further, the invention relates to the constitutive of cell lines that stably or transiently co-express a combination of T1R1 and T1R3; or T1R2 and T1R3; under constitutive or inducible conditions. The use of these cells lines in cell-based assays to identify umami and sweet taste modulatory compounds is also provided, particularly high throughput screening assays that detect receptor activity by use of fluorometric imaging. | 09-03-2009 |
20090269843 | Hemopexin fusion proteins - Fusion proteins comprising a first protein fused to hemopexin are provided, said fusion proteins exhibit an increased circulation time. | 10-29-2009 |
20090286314 | Fluorescent proteins and genes encoding them - Fluorescent proteins comprising the following internal amino acid sequence | 11-19-2009 |
20090298167 | INTERLEUKIN-21 RECEPTOR BINDING PROTEINS - The present invention provides binding proteins and antigen-binding fragments thereof that specifically bind to the human interleukin-21 receptor (IL-21R). The binding proteins can act as, e.g., antagonists of IL-21R activity, thereby modulating immune responses in general, and those mediated by IL-21R in particular. The disclosed compositions and methods may be used, e.g., in diagnosing and/or treating IL-21R-associated disorders, e.g., inflammatory disorders, autoimmune diseases, allergies, transplant rejection, cancer, and other immune system disorders. | 12-03-2009 |
20100099183 | VECTORS AND METHODS FOR ENHANCED CELL LONGEVITY AND PROTEIN EXPRESSION - It is the object of the current invention to provide methods and compositions relating to the expression of vankyrin proteins in cell lines to increase their viability, longevity and capacity for protein production. The inventors have discovered that the expression of P-ank-1 and I | 04-22-2010 |
20100167394 | ULTRAMARINE FLUORESCENT PROTEIN - The present invention provides an artificial mutant of GFP having a novel emission peak, i.e., a fluorescent protein having an emission peak at 424 nm comprising an amino acid sequence represented by SEQ ID NO: 1, in which each of the amino acid residues at the 66th position and the 175th position is replaced and at least one of the amino acid residues at the 72nd position and the 206th position is further replaced, or a fluorescent protein having an emission peak at 424 nm and a pH-independent fluorescence intensity, in which each of the amino acid residues at the 65th, 145th, 148th, 46th and/or 203rd positions is further substituted. The fluorescent protein of the invention emits fluorescence having an emission peak at 424 nm and can be visually distinguished by its ultramarine color from other fluorescent proteins. The fluorescent protein has a pH-independent fluorescence intensity which is not affected by pH changes. | 07-01-2010 |
20100178698 | TISSUE CULTURE DEVICE - A tissue culture device includes a container having one or more upstanding walls extending upwardly from a floor. The floor of the container has a media having nutrients or growth substances therein. A plurality of plant tissues are within the container compartment and are placed upon a screen between the plant tissues and the media. The screen is tamped downwardly onto the media so that the plant tissues can get nutrients from the media, and so that waste products are transferred into the media. The screen is also removable through the open end of the container so as to remove all of the plurality of the plant tissues from the container at once. The plant tissue device can then be placed in another container having any cultured media as needed for the correct maintenance, propagation and development of plant tissue in culture. | 07-15-2010 |
20100221824 | Methods and compositions for transposition using minimal segments of the eukaryotic transformation vector piggyBac - The present invention provides a method for transforming an insect genome that has a much enhanced transformation frequency. The vectors and plasmids employed in the method are further described as transposition vectors that include a minimal amount of nucleotide sequence homologous to a 5′ region and a 3′ region of a native piggyBac nucleic acid sequence. The transformed cells or embryos may also be developed into transgenic organisms. Disclosed are minimal piggyBac-based plasmid constructs that comprises a minimal nucleic acid sequence homologous to a 5′ end of a piggyBac nucleic acid sequence (about 60-80 bp, particularly 66 bp) and a relatively long (300 to about 380 bp, particularly 311 by or 378 bp) continuous nucleic acid sequence homologous to a 3′ end of a piggyBac native nucleic acid sequence. Methods employing these constructs include the use of a helper plasmid. Transformation frequencies employing the constructs are enhanced 100-fold or higher over that transformation frequency obtained using other than the herein described constructs. | 09-02-2010 |
20100248360 | HUMAN T2R51 TASTE RECEPTOR NUCLEIC ACID SEQUENCES AND POLYPEPTIDES - Newly identified mammalian taste-cell-specific G Protein-Coupled Receptors and the genes encoding said receptors are described. Specifically, T2R taste G Protein-Coupled Receptors that are believed to be involved in bitter taste sensation, and the genes encoding the same, are described, along with methods for isolating such genes and for isolating and expressing such receptors. Methods for representing taste perception of a particular tastant in a mammal are also described, as are methods for generating a novel molecules or combinations of molecules that elicit a predetermined taste perception in a mammal, and methods for simulating one or more tastes. | 09-30-2010 |
20100261271 | Regulation of endogenous gene expression in cells using zinc finger proteins - The present invention provides methods for modulating expression of endogenous cellular genes using recombinant zinc finger proteins. | 10-14-2010 |
20100261272 | Compositions for Reducing Cell Adhesion to Bubbles - Compositions and methods for reducing gas-cell surface interface damage include a protective composition having at least sugar moiety where the sugar moiety provides a hydrophilic component to the protective composition. | 10-14-2010 |
20100261273 | Mammalian Receptor Proteins; Related Reagents and Methods - Nucleic acids encoding mammalian, e.g., primate, receptors, purified receptor proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are described. | 10-14-2010 |
20100291676 | HUMANIZED ANTI-CD4 ANTIBODY WITH IMMUNOSUPPRESSIVE PROPERTIES - A humanized antibody derived from mouse monoclonal anti-CD4 antibody B-F5 is able to activate CD25+CD4+ regulatory T cells and is useful for preparing immunosuppressive compositions. | 11-18-2010 |
20110065185 | MUTATED ANTI-CD22 ANTIBODIES WITH INCREASED AFFINITY TO CD22-EXPRESSING LEUKEMIA CELLS - Recombinant immunotoxins are fusion proteins composed of the Fv domains of antibodies fused to bacterial or plant toxins. RFB4 (Fv)-PE38 is an immunotoxin that targets CD22 expressed on B cells and B cell malignancies. The present invention provides antibodies and antibody fragments that have improved ability to bind the CD22 antigen of B cells and B cell malignancies compared to RFB4. Immunotoxins made with the antibodies and antibody fragments of the invention have improved cytotoxicity to CD22-expressing cancer cells. Compositions that incorporate these antibodies into chimeric immunotoxin molecules that can be used in medicaments and methods for inhibiting the growth and proliferation of leukemia and lymphoma cells. | 03-17-2011 |
20110065186 | EX-VIVO PRIMING FOR GENERATING CYTOTOXIC T LYMPHOCYTES SPECIFIC FOR NON-TUMOR ANTIGENS TO TREAT AUTOIMMUNE AND ALLERGIC DISEASE - Cytotoxic T lymphocytes (CTLs) specific for antigenic peptides derived from IgE molecule can be generated in vitro by stimulating resting naive CD8 T cells with IgE peptides presented by artificial antigen presenting cells. The IgE specific CTLs lyse the target cells loaded with IgE peptides in vitro and inhibit antigen specific IgE response in vivo. In addition, adoptive transfer of the IgE specific CTL to an asthmatic mouse model can inhibit the development of lung inflammation and airway hypersensitivity. IgE specific CTL provides a treatment for allergic asthma and other IgE-mediated allergic diseases. Antigenic peptides identified from non-tumor self-antigens induce specific cytotoxic T lymphocyte (CTL) in vitro. The CTL induced by peptides identified from CD40L can kill activated CD4 T cells. In vitro generated CTL specific for CD40L inhibit CD4-dependent antibody responses of all isotypes in vivo. In contrast, CTL induced by antigenic peptides derived from IgE specifically inhibit IgE responses, and adoptive transfer of CD40L-specific CTL to NOD mice at early age delay the development of diabetes in NOD mice. In vitro generated CTL specific for non-tumor self-antigens expressed on activated CD4 T cells regulate immune responses in vivo. | 03-17-2011 |
20110065187 | EX-VIVO PRIMING FOR GENERATING CYTOTOXIC T LYMPHOCYTES SPECIFIC FOR NON-TUMOR ANTIGENS TO TREAT AUTOIMMUNE AND ALLERGIC DISEASE - Cytotoxic T lymphocytes (CTLs) specific for antigenic peptides derived from IgE molecule can be generated in vitro by stimulating resting naive CD8 T cells with IgE peptides presented by artificial antigen presenting cells. The IgE specific CTLs lyse the target cells loaded with IgE peptides in vitro and inhibit antigen specific IgE response in vivo. In addition, adoptive transfer of the IgE specific CTL to an asthmatic mouse model can inhibit the development of lung inflammation and airway hypersensitivity. IgE specific CTL provides a treatment for allergic asthma and other IgE-mediated allergic diseases. Antigenic peptides identified from non-tumor self-antigens induce specific cytotoxic T lymphocyte (CTL) in vitro. The CTL induced by peptides identified from CD40L can kill activated CD4 T cells. In vitro generated CTL specific for CD40L inhibit CD4-dependent antibody responses of all isotypes in vivo. In contrast, CTL induced by antigenic peptides derived from IgE specifically inhibit IgE responses, and adoptive transfer of CD40L-specific CTL to NOD mice at early age delay the development of diabetes in NOD mice. In vitro generated CTL specific for non-tumor self-antigens expressed on activated CD4 T cells regulate immune responses in vivo. | 03-17-2011 |
20110091969 | MUTATIONS IN THE NS5B PROTEIN OF THE HCV - An NS5B protein of the hepatitis C virus (HCV), with good replication performance, has a point mutation in at least one of the following positions:
| 04-21-2011 |
20110136227 | OPTIMISATION OF EXPRESSION OF PARVOVIRAL REP AND CAP PROTEINS IN INSECT CELLS - The present invention relates to the improved production of recombinant parvoviral virions in insect cells. In particular, the invention relates to an improved process for the production of recombinant parvoviral virions in insect cells, wherein the full/empty parvoviral virion ratio is increased. The invention also relates to the production of parvoviral vectors that may be used in gene therapy and to improvements in expression of the viral Rep proteins that increase the productivity of parvoviral vectors. | 06-09-2011 |
20110171728 | Method and composition for crystallizing G protein-coupled receptors - Certain embodiments provide a method for crystallizing a GPCR. The method may employ a fusion protein comprising: a) a first portion of a G-protein coupled receptor (GPCR), where the first portion comprises the TM1, TM2, TM3, TM4 and TM5 regions of the GPCR; b) a stable, folded protein insertion; and c) a second portion of the GPCR, where the second portion comprises the TM6 and TM7 regions of the GPCR. | 07-14-2011 |
20110207214 | NOVEL TOOLS FOR THE PRODUCTION OF GLYCOSYLATED PROTEINS IN HOST CELLS - The invention improves glycoprotein production and protein glycosylation engineering in eukaryotes, specifically the production of human-like complex or hybrid glycosylated proteins in lower eukaryotes such as yeasts. The invention provides glycosylation modified eukaryotic host cells capable of producing glycosylation optimized proteins useful as immunoglobulins and other therapeutic proteins, and provides cells capable of producing glycoproteins having glycan structures similar to glycoproteins produced in human cell. The invention further provides proteins with human-like glycan structures and novel compositions thereof producible by these cells. | 08-25-2011 |
20110229964 | Fusion Protein Delivery System and Uses Thereof - The present invention provides a composition of matter, comprising: DNA encoding a viral Vpx protein fused to DNA encoding a protein. In another embodiment of the present invention, there is provided a composition of matter comprising: DNA encoding a viral Vpr protein fused to DNA encoding a protein. The present invention further provides DNA, vectors and methods for expressing a lentiviral pol gene in trans, independent of the lentiviral gag-pol. A gene transduction element is optionally delivered to a lentiviral vector according to the present invention. Also provided are various methods of delivering a virus inhibitory molecule to a target in an animal. Further provided is a pharmaceutical composition. | 09-22-2011 |
20110236970 | CHAMBER OF A BIOREACTOR PLATFORM - Disclosed herein is mesoscale bioreactor platform comprising an upwards open chamber for a biological cell, which chamber via a first port is in communication with a first channel for conducting an influent stream of a liquid into the chamber and via a second port is in communication with a second channel for conducting an effluent stream of a liquid away from the chamber, which chamber is provided with a closure comprising a water-immiscible liquid, and wherein said first channel is in fluid communication with a reservoir for a liquid and said second channel is in fluid communication with a waste container. Furthermore, a method for modifying the interaction of a content of a chamber with the surroundings is described as well as method of culturing a biological cell. | 09-29-2011 |
20110250683 | Thermophilic and thermoacidophilic sugar transporter genes and enzymes from alicyclobacillus acidocaldarius and related organisms, methods - Isolated and/or purified polypeptides and nucleic acid sequences encoding polypeptides from | 10-13-2011 |
20110275150 | COMPSTATIN ANALOGS WITH IMPROVED ACTIVITY - Compounds comprising peptides and peptidomimetics capable of binding the C3 protein and inhibiting complement activation are disclosed. These compounds display improved complement activation-inhibitory activity as compared with currently available compounds. Isolated nucleic acid molecules encoding the peptides are also disclosed. | 11-10-2011 |
20110281349 | Insect Desiccation Resistance Genes and Uses Thereof - An objective of the present invention is to provide polynucleotides encoding insect desiccation resistance proteins, and uses thereof cDNA libraries were produced from | 11-17-2011 |
20110306125 | Protein Expression Methods - The present invention relates to compositions and methods for obtaining (e.g., expressing, isolating and/or purifying) polypeptides capable of binding to and/or activating the guanylate cyclase C receptor. | 12-15-2011 |
20120034691 | GENETICALLY ENCODED CALCIUM INDICATORS AND METHODS OF USE - Provided herein are nucleic acid sequences and polypeptides encoding a genetically encoded calcium indicator (GECI). Also provided are vectors and cells comprising the nucleic acid sequences and/or polypeptides. Kits comprising the nucleic acid sequences, polypeptides, vectors, cells and combinations thereof are also provided. Also provided herein are methods of screening for G-protein coupled receptor (GPCR) agonists and antagonists and methods of monitoring neural activity using the GECIs. | 02-09-2012 |
20120040455 | CURVED POLYHEDRONS - The present invention relates to a polymer article having the shape of a curved polyhedron comprising only concave curvature faces and convex curvature edges or by also having concave curvature faces, in which a part of the concave curvature face has been replaced by a flat face, and convex curvature edges optionally comprising imbedded material. Another aspect of the present invention regards the use of said polymer article as well as a process for the production of such a polymer article | 02-16-2012 |
20120040456 | METHODS OF GENE THERAPY USING NUCLEIC ACID SEQUENCES FOR ATP-BINDING CASSETTE TRANSPORTER - The present invention provides nucleic acid and amino acid sequences of an ATP binding cassette transporter and mutated sequences thereof associated with macular degeneration. Methods of detecting agents that modify ATP-binding cassette transporter comprising combining purified ATP binding cassette transporter and at least one agent suspected of modifying the ATP binding cassette transporter an observing a change in at least one characteristic associated with ATP binding cassette transporter. Methods of detecting macular degeneration is also embodied by the present invention. | 02-16-2012 |
20120045829 | IDENTIFICATION OF ANTIGENIC PEPTIDES FROM MULTIPLE MYELOMA CELLS - Multiple myeloma (MM) is a clonal B cell malignancy and remains essentially incurable by conventional anti-tumor therapy. Patients with MM have a median survival of only three years. MM is characterized by proliferation and accumulation of mature plasma cells in the bone marrow (BM) leading to bone destruction, BM failure, anemia, and reduced immune function. The identification of MHC Class I, HLA-A2, associated peptides presented on multiple myeloma cells is an important step in developing immunotherapies for MM. Presented here are methods for creating activated T lymphocytes that are cytotoxic to both peptide loaded T2 target cells and multiple myeloma cell lines. | 02-23-2012 |
20120064621 | Cell Culture Compositions Capable of Producing a VEGF-Binding Fusion Polypeptide - The present invention provided cell culture compositions capable of producing fusion polypeptides that bind vascular endothelial growth factor (VEGF). The cell culture compositions of the invention comprise cells which contain an expression vector comprising a nucleic acid molecule encoding a fusion polypeptide that binds VEGF. The fusion polypeptides may comprise a VEGF receptor component having immunoglobulin-like (Ig) domain 2 of a first VEGF receptor, an Ig domain 3 of a second VEGF receptor, and a multimerizing component. | 03-15-2012 |
20120064622 | Methods and Systems for Chemoautotrophic Production of Organic Compounds - The present disclosure identifies pathways, mechanisms, systems and methods to confer chemoautotrophic production of carbon-based products of interest, such as sugars, alcohols, chemicals, amino acids, polymers, fatty acids and their derivatives, hydrocarbons, isoprenoids, and intermediates thereof, in organisms such that these organisms efficiently convert inorganic carbon to organic carbon-based products of interest using inorganic energy, such as formate, and in particular the use of organisms for the commercial production of various carbon-based products of interest. | 03-15-2012 |
20120094377 | Modified Fluorescent Proteins and Methods for Using Same - Nucleic acid molecules encoding improved fluorescent mutants of the mKate2 protein, variants and derivatives thereof are provided, as well as proteins and peptides encoded by these nucleic acids. Also provided are proteins that are substantially similar to, or derivatives, homologues, or mutants of, the above-referenced specific proteins. Also provided are fragments of the nucleic acids and the peptides encoded thereby, as well as antibodies specific to the proteins and peptides of the invention. In addition, host-cells, stable cell lines and transgenic organisms comprising above-referenced nucleic acid molecules are provided. The subject protein and nucleic acid compositions find use in a variety of different applications and methods, particularly for labeling of biomolecules, cells or cell organelles. Finally, kits for use in such methods and applications are provided. | 04-19-2012 |
20120100606 | Inducible System for Highly Efficient Production of Recombinant Adeno-Associated Virus (rAAV) Vectors - Production of clinical grade gene therapy vectors for human trials remains a major hurdle in advancing cures for a number of otherwise incurable diseases. Disclosed herein are systems based on a stably trans formed insect cell lines harboring helper genes required for vector production. Specifically exemplified are system embodiments that take advantage of DNA regulatory elements from two unrelated viruses—AcMNPV and AA V2. System embodiments utilize rep and/or cap genes either stably transfected in cell lines or which are introduced into cells as an expression cassette in a vector. Rep and cap genes that are designed to remain silent until the cell is infected with a viral vector. Infection with viral initiates rescue/amplification of integrated AAV helper genes resulting in dramatic induction of the expression and assembly of rAAV. The arrangement of this specific embodiment provides high levels of Rep and Cap proteins in every cell thus improving rAAV yields by 10-fold. The described vectors are modular in design and may be utilized for the production of other multiprotein complexes. | 04-26-2012 |
20120107929 | Variable Lymphocyte Receptors, Related Polypeptides and Nucleic Acids, and Uses Thereof - Disclosed are compositions and methods related to variable lymphocyte receptors (VLRs). | 05-03-2012 |
20120115223 | PREPARATION OF INACTIVATED ARTIFICIAL ANTIGEN PRESENTING CELLS AND THEIR USE IN CELL THERAPIES - Methods of processing inactivated artificial antigen presenting cells (aAPCs) and artificial antigen presenting cells with specificity for selected antigenic peptides are described, including their generation and use in cell therapy compositions comprising activated cytotoxic T lymphocytes. Inactivated aAPCs are advantageously generated through crosslinking, such as via a photoreaction involving a psoralen derivative and UVA irradiation. | 05-10-2012 |
20120129254 | Inducible Expression System Transcription Modulators Comprising A Distributed Protein Transduction Domain And Methods For Using The Same - Aspects of the invention include inducible expression systems in which a transcription modulator having a distributed protein transduction domain is employed. Aspects of the invention further include methods of using the systems to induce expression of a coding sequence, as well as kits that find use in practicing methods of the invention. The systems, components thereof, methods and kits find use in a variety of different applications. | 05-24-2012 |
20120149101 | METHODS AND KITS FOR REGULATING INTRACELLULAR TRAFFICKING OF A TARGET PROTEIN - A method and kits for regulating the intracellular trafficking of a target protein. In a retained state, the target protein is retained in a first compartment by an interaction with a hook protein. In a released state, the interaction is disrupted and the target protein traffics to a target compartment. | 06-14-2012 |
20120156770 | HUMAN ANDROGEN RECEPTOR ALTERNATIVE SPLICE VARIANTS - The present invention relates to novel androgen receptor splice variants (AR3, AR4, AR4b, AR5 and AR8) and variants and fragments thereof which have a role in the progression of androgen independent prostate cancer. The invention further relates to compositions and methods which can be used to identify and treat prostate cancer based on these novel androgen receptor splice variants, as well as methods for screening agents which modulate the activity and/or expression of the androgen receptor splice variants. Vectors, host cells and recombinant methods for producing the same and transgenic animals are also provided. | 06-21-2012 |
20120171765 | Factor VII or VIIa - Like Molecules - Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided. | 07-05-2012 |
20120190107 | ENHANCED PROTEIN TRANSDUCTION - Methods of enhanced protein transduction are provided. Aspects of the methods include contacting a cell with a transduction protein, where the transduction protein includes both a protein-of-interest domain and a protein transduction domain, and a nucleic acid transfection agent. Also provided are systems and kits that find use in practicing methods according to embodiments of the invention. The methods, systems and kits find use in a variety of different applications. | 07-26-2012 |
20120220029 | MUTANT SOX PROTEINS AND METHODS OF INDUCING PLURIPOTENCY - There is presently provided mutant Sox2, Sox7 and Sox17 proteins that have acquired or increased ability to induce pluripotency in a partially differentiated or fully differentiated cell. Sox7 and Sox17 are mutated to resemble in part Sox2, or Sox2 is mutated to resemble in part Sox7 or Sox17. In one aspect, the Oct4 contact interface of Sox7 or Sox17 is mutated. In another aspect, the high mobility group (HMG) of Sox2 is fused to the C-terminal activation domain of Sox7 or Sox17. Methods relating to inducing pluripotency using a mutant Sox2, Sox7 or Sox17 protein are also provided. | 08-30-2012 |
20120244615 | ISOLATED A-TYPE FHF N-TERMINAL DOMAIN PEPTIDES AND METHODS OF USE - Isolated peptides are provided that are effective in inducing long-term inactivation of voltage-gated sodium channels (VGSCs) in mammalian cells. Such peptides are useful in reducing the action potentials of these excitable cells, for example, neurons, myocytes, and tonic muscle cells, in mammals in need thereof. | 09-27-2012 |
20120252118 | PLASTIC PRESSURE VESSEL FOR BIOPHARMACEUTICAL APPLICATIONS AND METHODS THEREOF - Described herein is a molded plastic pressure vessel for biopharmaceutical applications and methods thereof. The molded plastic pressure vessel has a surface area of at least 500 inches2 and comprises a polyphenylene oxide polymer; and at least one antioxidant. | 10-04-2012 |
20120282689 | Expanding the Eukaryotic Genetic Code - This invention provides compositions and methods for producing translational components that expand the number of genetically encoded amino acids in eukaryotic cells. The components include orthogonal tRNAs, orthogonal aminoacyl-tRNA synthetases, orthogonal pairs of tRNAs/synthetases and unnatural amino acids. Proteins and methods of producing proteins with unnatural amino acids in eukaryotic cells are also provided. | 11-08-2012 |
20120295345 | APPARATUSES AND RELATED METHODS FOR DELIVERING BIOLOGICAL MATERIAL INTO A CELL - Systems, devices, and methods for protecting a biological material during delivery into a biological structure are provided. In one aspect, for example, a device for protecting and delivering a preselected biological material into a biological structure can include a lance operable to maintain a charge capable of associating a biological material thereto and at least one protective region formed on or in the lance, where the protective region protects the biological material during delivery into a biological structure. | 11-22-2012 |
20120309085 | Variant Forms of Urate Oxidase and Use Thereof - Genetically modified proteins with uricolytic activity are described. Proteins comprising truncated urate oxidases and methods for producing them, including PEGylated proteins comprising truncated urate oxidase are described. | 12-06-2012 |
20120322147 | DIRECT PROTEIN DELIVERY WITH ENGINEERED MICROVESICLES - The present invention relates to direct protein delivery with engineered micro vesicles. | 12-20-2012 |
20120329150 | METHODS AND COMPOSITIONS FOR EXPRESSING NEGATIVE-SENSE VIRAL RNA IN CANINE CELLS - The present invention provides novel canine pol I regulatory nucleic acid sequences useful for the expression of nucleic acid sequences in canine cells such as MDCK cells. The invention further provides expression vectors and cells comprising such nucleic acids as well as methods of using such nucleic acids to make influenza viruses, including infectious influenza viruses. | 12-27-2012 |
20130011919 | Mammalian alpha-kinase proteins, nucleic acids and diagnostic and therapeutic uses thereof - The present invention provides novel mammalian alpha-kinase proteins: melanoma alpha-kinase (MK), heart alpha-kinase (HK), kidney alpha-kinase (KK), skeletal muscle alpha-kinase (SK), and lymphocyte alpha-kinase (LK). In particular, a novel kinase type is herein provided, characterized by the presence of an alpha-kinase catalytic domain and an ion channel domain. Isolated nucleic acids of the alpha-kinases MK, HK, KK, SK and LK are provided. Methods for making the novel alpha-kinases, cells that express the alpha-kinases and methods for treating an animal in need of either increased or decreased activity of the alpha-kinases are provided. | 01-10-2013 |
20130017597 | USE OF BIOLOGICAL PHOTORECEPTORS AS DIRECTLY LIGHT-ACTIVATED ION CHANNELS - Use of a biological photoreceptor as light-controlled ion channel for the alteration of the ion conductivity of a membrane by means of light. The photoreceptor used comprises an apoprotein and a light-sensitive polyene covalently bound to the apoprotein, said polyene interacting with the apoprotein and functioning as a light-sensitive gate. | 01-17-2013 |
20130029413 | Methods of Using a Bacterial GlcNAc-6-P 2'- Epimerase to Promote Sialylation of Glycoconjugates - The present invention relates to new methods to promote sialylation of glycoconjugates, including recombinant glycoproteins, in glycoconjugate production systems. The invention relates to methods to promote efficient glycoconjugate sialylation in recombinant expression systems, by providing simpler and more economical ways to produce large intracellular pools of sialic acid precursors. The invention is directed to nucleic acids, vectors, and cells harboring vectors comprising nucleic acids encoding enzymes involved in the synthesis of sialic acid precursors, and cells harboring these nucleic acids in combination with nucleic acids encoding glycosyltransferases, including sialyltransferases, to facilitate the production of humanized recombinant glycoproteins in bacterial, fungal, plant, and animal cell expression systems. The engineered cells can be used to produce glycosylated proteins in virally-infected, transiently-transformed, or stably-transformed host cells, including lepidopteran insects and cultured cell lines derived from | 01-31-2013 |
20130034900 | REPROGRAMMATION OF EUKARYOTIC CELLS WITH ENGINEERED MICROVESICLES - The present invention relates to a non-genetic, detergent-free, bacteria-free method for reprogramming a eukaryotic cell, in particular for obtaining induced pluripotent stem cells (iPS), by using engineered microvesicles carrying at least one reprogramming transcription factor, wherein said engineered microvesicles are virus-free. | 02-07-2013 |
20130122585 | SYNTHETIC GAGPOL GENES AND THEIR USES - The present invention relates to synthetic gag and gagpol genes optimized for high level expression via codon optimization and the uses thereof for the efficient generation of vector particles. The invention further relates to the generation of packaging cells and vaccines based on the synthetic gag and gagpol genes. | 05-16-2013 |
20130171727 | T1R TASTE RECEPTORS AND GENES ENCODING SAME - Newly identified mammalian taste-cell-specific G protein-coupled receptors, and the genes and cDNA encoding said receptors are described. Specifically, T1R G protein-coupled receptors active in taste signaling, and the genes and cDNA encoding the same, are described, along with methods for isolating such genes and for isolating and expressing such receptors. Methods for representing taste perception of a particular tastant in a mammal are also described, as are methods for generating novel molecules or combinations of molecules that elicit a predetermined taste perception in a mammal, and methods for simulating one or more tastes. Further, methods for stimulating or blocking taste perception in a mammal are also disclosed. | 07-04-2013 |
20130177978 | IMMUNOREACTIVE EHRLICHIA P120/P140 EPITOPES AND USES THEREOF - Provided herein are immunoreactive peptides which can selectively bind | 07-11-2013 |
20130177979 | METHODS AND COMPOSITIONS FOR CELL PERMEABLE STAT3 INHIBITOR - Disclosed herein are compositions for inhibition of Stat, particularly Stat3. Disclosed herein are compositions comprising cell permeable Stat3 inhibitors. Compositions may comprise peptides, polypeptides, antibodies, nucleic acids, vectors, and host cells for making, using, assaying, and evaluating Stat3 inhibitors. Disclosed herein are methods for making and using the disclosed compositions. | 07-11-2013 |
20130196430 | PROTEIN PRODUCTION - The invention concerns the field of protein production and cell culture technology. CERT is identified as a novel in vivo PKD substrate. Phosphorylation on serine 132 by PKD decreases the affinity of CERT towards its lipid target phosphatidylinositol 4-phosphate at Golgi membranes and reduces ceramide transfer activity, identifying PKD as a regulator of lipid homeostasis. The present invention shows that CERT in turn is critical for PKD activation and PKD dependent protein cargo transport to the plasma membrane. The interdependence of PKD and CERT is thus a key to the maintenance of Golgi membrane integrity and secretory transport. | 08-01-2013 |
20130203162 | NOVEL FLUORESCENT PROTEINS AND METHODS FOR USING SAME - The present invention provides nucleic acid molecules encoding novel red fluorescent proteins from | 08-08-2013 |
20130203163 | PROMISCUOUS PAP CD4 T CELL EPITOPES - The present invention relates to the discovery of novel T cell epitopes of the human prostatic acid phosphatase (PAP) protein that is promiscuous for at least 15 different HLA-DR alleles. The invention also relates to compositions that contain one of the novel epitopes or a fusion peptide of such an epitope and a heterologous polypeptide. Further disclosed herein is the use of the epitopes or their fusion peptides, and compositions containing the epitopes or their fusion peptides. | 08-08-2013 |
20130224855 | CULTURE MEDIUM FOR EUKARYOTIC CELLS - The invention pertains to the use of amino acid derivatives selected from N-acetyl amino acids, γ-glutamyl amino acids, pyroglutamyl amino acids, glutamate-containing or proline-containing dipeptides, oxo-aminoacids, homo-aminoacids, and glycyl-glycine, as a growth- and production promoting ingredient, in culture media for culturing eukaryotic cells. The invention further pertains to culture media containing these amino acid derivatives at levels of at least 0.001 mg/l. | 08-29-2013 |
20130295666 | CRYSTALS OF GLUCOKINASE REGULATORY PROTEIN (GKRP) - The present invention pertains to crystals of glucokinase regulatory protein (GKRP) and of GKRP variants, to the molecular biology of certain GKRP variants, to processes for the crystallization of GKRP and GKRP variants, to such crystals and corresponding structural information obtained by X-ray crystallography. Such crystals and crystallographic data can be used for the identification of compounds that bind to GKRP, especially of compounds that inhibit GKRP or interfere with the interaction of GKRP with its natural interacting partner Glucokinase (GK). | 11-07-2013 |
20140004603 | UROCORTIN-III AND USES THEREOF | 01-02-2014 |
20140045261 | SITE-SPECIFIC INCORPORATION OF AMINO ACIDS INTO MOLECULES - The invention provides certain embodiments relating to methods and compositions for incorporating non-natural amino acids into a polypeptide or protein by utilizing a mutant or modified aminoacyl-tRNA synthetase to charge the non-natural amino acid to a the corresponding tRNA. In certain embodiments, the tRNA is also modified such that the complex forms strict Watson-Crick base-pairing with a codon that normally forms wobble base-pairing with unmodified tRNA/aminoacyl-tRNA synthetase pairs. | 02-13-2014 |
20140057349 | Steroidal Ligands and Their Use in Gene Switch Modulation - The present invention relates to steroidal ligands for use in nuclear receptor-based inducible gene expression systems. The invention further relates to methods of modulating the expression of genes of interest with a system containing one or more nuclear receptor complexes and one or more steroidal ligands. Further aspects include ligand compositions including therapeutic compositions. | 02-27-2014 |
20140087458 | METHODS AND COMPOSITIONS FOR PRODUCING VITAMIN K DEPENDENT PROTEINS - The present invention relates to methods and compositions for improving the productivity of recombinant vitamin K dependent protein expression in host cells. | 03-27-2014 |
20140127801 | OPTIMIZATION OF EXPRESSION OF PARVOVIRAL REP AND CAP PROTEINS IN INSECT CELLS - The present invention relates to the improved production of recombinant parvoviral virions in insect cells. In particular, the invention relates to an improved process for the production of recombinant parvoviral virions in insect cells, wherein the full/empty parvoviral virion ratio is increased. The invention also relates to the production of parvoviral vectors that may be used in gene therapy and to improvements in expression of the viral Rep proteins that increase the productivity of parvoviral vectors. | 05-08-2014 |
20140134722 | Mammalian alpha-kinase proteins, nucleic acids and diagnostic and therapeutic uses thereof - The present invention provides novel mammalian alpha-kinase proteins: melanoma alpha-kinase (MK), heart alpha-kinase (HK), kidney alpha-kinase (KK), skeletal muscle alpha-kinase (SK), and lymphocyte alpha-kinase (LK). In particular, a novel kinase type is herein provided, characterized by the presence of an alpha-kinase catalytic domain and an ion channel domain. Isolated nucleic acids of the alpha-kinases MK, HK, KK, SK and LK are provided. Methods for making the novel alpha-kinases, cells that express the alpha-kinases and methods for treating an animal in need of either increased or decreased activity of the alpha-kinases are provided. | 05-15-2014 |
20140141508 | Recombinant Carrier Molecule for Expression, Delivery and Purification of Target Polypeptides - Recombinant carrier molecules having amino acid sequences from thermostable enzymes and methods of use for expression, recovery and delivery of foreign sequences (peptides and polypeptides) produced in different systems (bacteria, yeast, DNA, cell cultures such as mammalian, plant, insect cell cultures, protoplast and whole plants in vitro or in vivo are provided. The recombinant carrier molecule using sequences from lichenase B (Lic B) were also made and used as part of carrier protein to express, recover and deliver a variety of target polypeptides of interest. | 05-22-2014 |
20140170747 | CAP FILTRATION TOOL AND TRANSFER SYSTEM - A cap has recess containing a porous frit and a graded porosity filter located so fluid from a container to which the cap is connected passes through the filter and out a spout on the cap. The filter porosity is selected to pass product expressed from cellular organisms grown in growth media inside the container while filtering out debris. A cap vent allows positive pressure in the container ullage to expedite filtering and reduce agitation of the container contents. This is not just a cap with a filter but an enabling tool. This tool enables total design change in many processes from previous thinking, allowing for the maximization of purified material, and reduction of multiple steps. | 06-19-2014 |
20140178985 | BETA 1,4-GALACTOSYLTRANSFERASES WITH ALTERED DONOR AND ACCEPTOR SPECIFICITIES, COMPOSITIONS AND METHODS OF USE - The invention relates generally to beta (1,4)-galactosyltransferase I mutants having altered donor and acceptor specificities, and methods of use thereof. In addition, the invention relates to methods for synthesizing oligosaccharides using the beta (1,4)-galactosyltransferase I mutants and to using the beta (1,4)-galactosyltransferase I mutants to conjugate agents, such as therapeutic agents or diagnostic agents, to acceptor molecules. | 06-26-2014 |
20140178986 | SOLUBLE INHIBITORS OF VASCULAR ENDOTHELIAL GROWTH FACTOR AND USE THEREOF - The present invention relates to cDNA encoding a soluble neuropilin protein (sNP) which is isolated from neuropilin (NP) producing cells or is recombinantly engineered from NP-encoding DNA. NP-1 and NP-2 are preferred NPs but any neuropilin or VEGF receptor (VEGFR), where the constituents share at least about 85% homology with either of the above VEGF | 06-26-2014 |
20140220679 | METHODS AND COMPOSITIONS FOR CATEGORIZING PATIENTS - The disclosure provides, among other things, molecular markers for categorizing the neoplastic state of a patient, methods for using the molecular markers in diagnostic tests, nucleic acid and amino acid sequences related to the molecular markers, reagents for detection of molecular markers, and methods for identifying candidate molecular markers in highly parallel gene expression data. | 08-07-2014 |
20140242692 | MAMMALIAN GENES INVOLVED IN TOXICITY AND INFECTION - The present invention relates to cellular proteins that are involved in toxicity and infection or are otherwise associated with the life cycle of one or more pathogens. | 08-28-2014 |
20140273204 | Method Of Producing A Paralytic Peptide - The invention relates to recombinant expression vectors encoding a low molecular weight peptide isolated from the submaxiliary saliva glands of shrews of the species | 09-18-2014 |
20140273205 | ANIMAL CELL CULTURE MEDIA COMPRISING NON ANIMAL OR PLANT DERIVED NUTRIENTS - The present invention provides serum-free cell culture media formulations which are capable of supporting the in vitro cultivation of animal cells. The media comprise at least one nutrient of non-animal derivation, such as at least one plant peptide and/or at least one non-animal or plant lipid and/or fatty acid. The media may further optionally comprise an enzymatic digest or extract of yeast cells. The present invention also provides methods of cultivating animal cells in vitro using these cell culture media formulations. In addition, the media of the present invention can be used for growth of animal cells for virus production. | 09-18-2014 |
20140295543 | METHODS AND COMPOSITIONS RELATING TO POLYPEPTIDES WITH RNASE III DOMAINS THAT MEDIATE RNA INTERFERENCE - The present invention concerns methods and compositions involving RNase III and polypeptides containing RNase III domains to generate RNA capable of triggering RNA-mediated interference (RNAi) in a cell. In some embodiments, the RNase III is from a prokaryote. RNase III activity will cleave a double-stranded RNA molecule into short RNA molecules that may trigger or mediate RNAi (siRNA). Compositions of the invention include kits that include an RNase III domain-containing polypeptide. The present invention further concerns methods using polypeptides with RNase III activity for generating RNA molecules that effect RNAi, including the generation of a number of RNA molecules to the same target. | 10-02-2014 |
20140295544 | FLUORESCENT PROTEINS WITH INCREASED ACTIVITY IN CELLS - The present invention relates to fluorescent proteins, in particular green fluorescent proteins (GFPs), with increased activity in cells, and thus increased signal strength. A further aspect of the present invention relates to the use of peptides for increasing the expression and/or stability of a protein in a cell. | 10-02-2014 |
20140315299 | STABLE PROTEINS - The invention provides a fusion protein comprising, from N-terminus to C-terminus: a) a first portion of a Family B G-protein coupled receptor (GPCR) that comprises transmembrane helix (TM)-1, TM2 and TM3 of the GPCR; b) a stable protein domain; and c) a second portion of the GPCR comprising TM4, TM5, TM6 and TM7 of the GPCR. The invention also provides a method of crystallising a GPCR comprising providing the fusion protein of the invention and crystallising it to obtain crystals. | 10-23-2014 |
20140322807 | METHOD FOR EXTRACTING NUTRIENTS FROM ORGANIC MATERIALS - Processes for extracting and recovering nutrients from organic wastes to create a cell culture broth for microorganisms involve the main steps of mixing, solid/liquid separation, optimization, and sterilization. In an embodiment, the method for converting organic waste material into a cell culture broth or growth media includes: (a) mixing an organic waste material with one or more solvent to create a mixture of liquids and solids under substantially turbulent conditions; (b) separating the mixture of liquids and solids into a liquid stream and solid stream; and (c) sterilizing the liquid stream, whereby the cell culture broth or growth media comprises the sterilized liquid stream. | 10-30-2014 |
20140329313 | EXPRESSION IN INSECT CELLS OF GENES WITH OVERLAPPING OPEN READING FRAMES, METHODS AND COMPOSITIONS THEREFOR - The present teachings disclose nucleic acid cassettes for expressing in an insect cell a plurality of polypeptides encoded by a gene comprising overlapping open reading frames (ORFs). A cassette comprises, in 5′ to 3′ order, a) a first insect cell-operable promoter, b) a 5′ portion of a gene comprising a first ORF of the gene, c) an intron comprising a second insect cell-operable promoter, and d) a 3′ portion of the gene comprising at least one additional ORF. Vectors and insect cells comprising the cassettes are also disclosed, as well as methods for production of recombinant adeno-associated virus in insect cells using the cassettes. | 11-06-2014 |
20140342451 | METHODS OF INCORPORATING AMINO ACID ANALOGS INTO PROTEINS - The invention provides a method of incorporating nonstandard amino acids into a protein by utilizing a modified aminoacyl-tRNA synthetase to charge the nonstandard amino acid to a modified tRNA, which forms strict Watson-Crick base-pairing with a codon that normally forms wobble base-pairing with natural tRNAs. | 11-20-2014 |
20140356944 | BIOCATALYSTS AND METHODS FOR THE SYNTHESIS OF (S)-3-(1-AMINOETHYL)-PHENOL - The present disclosure provides engineered transaminase polypeptides having improved properties as compared to naturally occurring transaminases including the ability of converting the substrate, 3′-hydroxyacetophenone to (S)-3-(1-aminoethyl)-phenol in enantiomeric excess and high percentage conversion. Also provided are polynucleotides encoding the engineered transaminases, host cells capable of expressing the engineered transaminases, and methods of using the engineered transaminases to synthesize (S)-3-(1-aminoethyl)-phenol and related compounds useful in the production of active pharmaceutical ingredients. | 12-04-2014 |
20140370594 | BIOLOGICAL CONVERSION OF BIOMASS-DERIVED SUGARS TO VALUE ADDED CHEMICALS - A method of growing a microorganism by culturing the microorganism in a an aqueous solution of carbohydrates containing C6-sugar monomers or C5-sugar monomers, wherein the aqueous solution of carbohydrates is made by reacting biomass or a biomass-derived reactant with a solvent system including a lactone and water, and an acid catalyst. The reaction yields a product mixture containing water-soluble C6-sugar-containing oligomers, C6-sugar monomers, C5-sugar-containing oligomers, C5-sugar monomers, or any combination thereof. The product mixture is then partitioned or extracted to yield an aqueous layer containing the carbohydrates and a substantially immiscible organic layer containing the lactone. The aqueous layer is used for growing the microorganisms. | 12-18-2014 |
20140370595 | Use of Synthetic Scaffolds for the Production of Biosynthetic Pathway Products - The present invention provides methods of producing a product or product precursor of a biosynthetic pathway in a genetically modified host cell. The present invention also provides genetically modified host cells comprising nucleic acids encoding a scaffold polypeptide and nucleic acids comprising nucleotide sequences encoding two or more enzymes in a biosynthetic pathway. The present invention further provides nucleic acids comprising nucleotide sequences encoding scaffold polypeptides, for use in a subject method. | 12-18-2014 |
20150064782 | PRODUCTION OF FATTY ACID DERIVATIVES - The invention relates to compositions and methods, including polynucleotide sequences, amino acid sequences, recombinant host cells and recombinant host cell cultures engineered to produce fatty acid derivative compositions comprising fatty acids, fatty alcohols, fatty aldehydes, fatty esters, alkanes, terminal olefins, internal olefins or ketones. The fatty acid derivative composition is produced extracellularly with a higher titer, yield or productivity than the corresponding wild type or non-engineered host cell. | 03-05-2015 |
20150132845 | DEVICE AND METHOD FOR CONTINUOUS CELL CULTURE AND OTHER REACTIONS - Devices, systems, and methods for continuous cell culture and other reactions are generally described. In some embodiments, chambers (e.g., cell growth chambers) including at least a portion of a wall formed of a flexible member are provided. A retaining structure can be incorporated outside and proximate to the chamber such that when liquid is added to the chamber, the flexible member is consistently and predictably deformed, and a consistent volume of liquid is added. The flexible member can be formed of, in some embodiments, a gas-permeable medium. In some embodiments, reaction chambers can be arranged in a fluidic loop, and a bypass channel can be used to introduce and/or extract fluid from the loop without affecting loop operation. | 05-14-2015 |
20150299293 | T1R TASTE RECEPTORS AND GENES ENCODING SAME - Newly identified mammalian taste-cell-specific G protein-coupled receptors, and the genes and cDNA encoding said receptors are described. Specifically, T1R G protein-coupled receptors active in taste signaling, and the genes and cDNA encoding the same, are described, along with methods for isolating such genes and for isolating and expressing such receptors. Methods for representing taste perception of a particular tastant in a mammal are also described, as are methods for generating novel molecules or combinations of molecules that elicit a predetermined taste perception in a mammal, and methods for simulating one or more tastes. Further, methods for stimulating or blocking taste perception in a mammal are also disclosed. | 10-22-2015 |
20150299638 | METHODS AND SYSTEMS FOR OPTIMIZING PERFUSION CELL CULTURE SYSTEM - Methods and perfusion culture systems are disclosed. The systems and methods relate to decreasing the starting perfusion rate, resulting in increased residence time of the cells in the bioreactor and the cell retention device, and/or concomitantly increasing the starting bioreactor volume or decreasing the starting cell retention device volume, or both. Other method embodiments include increasing the concentrations of individual components of the tissue culture fluid, and adding a stabilizer of the degradation of the recombinant protein. | 10-22-2015 |
20150307584 | METHODS OF MODULATING COLD SENSORY PERCEPTION - The present invention relates to regulation of cold sensation and pain. More particularly, the present invention is directed to nucleic acids encoding a member of the transient regulatory protein family, CMR1, which is involved in modulation of the perception of cold sensations and pain. The invention further relates to methods for identifying and using agents that modulate cold responses and pain responses stimulated by cold via modulation of CMR1 and CMR1-related signal transduction. | 10-29-2015 |
20150315258 | GENETICALLY ENCODED CALCIUM INDICATORS AND METHODS OF USE - Genetically encoded calcium indicator (GECI) polypeptides and the nucleic acid molecules encoding such polypeptides are provided. In addition, methods of using such nucleic acids and polypeptides in methods of screening for agonists or antagonists of G-protein coupled receptor (GPCR) or ion channels and methods of monitoring neural activity also are provided. | 11-05-2015 |
20150353905 | CAS9-NUCLEIC ACID COMPLEXES AND USES RELATED THERETO - This disclosure relates to Cas9-nucleic acid complexes and uses related thereto. In certain embodiments, the disclosure contemplates transgenic plants and animals genetically engineered to express Cas9-nucleic acid complexes disclosed herein. In certain embodiments, the disclosure relates to methods of treating or preventing, diseases, conditions, cancer, viral infections or other pathogenic infection using vectors configured to express a Cas9-nucleic acid complex disclosed herein. | 12-10-2015 |
20150368315 | Nucleic acids encoding rage fusion proteins - The present invention provides novel therapeutics and methods of treatment for diseases associated with activation of the advanced glycation endproducts receptor (RAGE). | 12-24-2015 |
20150376627 | Inducible Expression System Transcription Modulators Comprising A Distributed Protein Transduction Domain And Methods For Using The Same - Aspects of the invention include inducible expression systems in which a transcription modulator having a distributed protein transduction domain is employed. Aspects of the invention further include methods of using the systems to induce expression of a coding sequence, as well as kits that find use in practicing methods of the invention. The systems, components thereof, methods and kits find use in a variety of different applications. | 12-31-2015 |
20160039909 | Fibronectin Type III Domain Based Scaffold Compositions, Methods and Uses - A protein scaffold based on a consensus sequence of fibronectin type III (FN3) proteins, such as the tenth FN3 repeat from human fibronectin (human Tenascin), including isolated nucleic acids that encode a protein scaffold, vectors, host cells, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices. In particular, protein scaffold molecules binding to IgG have been identified as useful for diagnostic and/or therapeutic applications. | 02-11-2016 |
20160052981 | REGULATORS OF NFAT - Disclosed are methods of identifying an agent that modulates an NFAT regulator protein. One such method comprises contacting at least one test agent with recombinant cell comprising at least one NFAT regulator protein or fragment or derivative thereof, assessing the effect of the test agent on an activity, interaction, expression, or binding to the NFAT regulator protein or fragment or derivative thereof, and identifying the test agent that has an effect on an activity, interaction, expression, or binding to the NFAT regulator protein or fragment or derivative thereof, whereby the identified test agent is characterized as an agent that modulates an NFAT regulator protein. Methods of identifying an agent that modulates intracellular calcium, methods to screen for an agent that modulates NFAT regulator function, methods to diagnose unexplained immunodeficiency in a subject, and methods for identifying an agent for treating or preventing a disease or disorder associated with a NFAT regulator protein or calcium signaling are also disclosed. | 02-25-2016 |
20160075752 | B-TYPE PLEXIN ANTAGONISTS AND USES THEREOF - The present invention concerns the field of cancer therapy. In particular, it relates to an antagonist of a B-type plexin which prevents the interaction of the B-type plexin with ErbB-2 for use as a medicament, in particular, for treating metastasizing cancer. The present invention also contemplates a method for identifying an antagonist which prevents the interaction of a B-type plexin with ErbB-2. Finally, the invention provides for a polynucleotide encoding a B-type plexin polypeptide which lacks a functional intracellular domain and the said polypeptide. | 03-17-2016 |
20160076043 | Methods for Improving Recombinant Protein Expression - Materials and methods are provided which allowed for increased expression of a transfected gene of interest in a recombinant host cell. | 03-17-2016 |
20160122413 | METHOD FOR PRODUCING ANTIBODY USING "NAKED" EXPRESSION VECTOR EXPRESSING TYPE II TRANSMEMBRANE FUSION PROTEIN - Methods are disclosed for generating antibodies and an expression vector used to express protein(s) which provoke the antibody response. The expression vector may be useful in generating an antibody directed to an antigen, comprising a gene in operable linkage with a promoter, which gene encodes upon expressing a fusion protein comprising (i) CD134L, a fragment, homologous or orthologues protein thereof as N-terminal moiety of the fusion protein; and (ii) all or part of an antigenic protein as C-terminal moiety of the fusion protein. To generate the antibodies, the vector is injected into a subject animal, which produces a fusion protein, against which antibodies are generated. | 05-05-2016 |
20160176941 | CD40L COLLECTIN FUSION PROTEINS | 06-23-2016 |
20160186212 | MODIFIED CELL BY PUTTING MATERIAL INTO THE CELL WITHOUT USING DELIVERY VEHICLE - The present invention relates to a modified cell prepared by putting material into the cell without using delivery vehicle and to a cell composition containing the modified cell. | 06-30-2016 |
20160194591 | BIOREACTOR WITH ADDITION TUBE | 07-07-2016 |
20160194662 | RECOMBINANT VIRUS-LIKE PARTICLES ENCODED BY MULTI-GENE VECTOR | 07-07-2016 |
20190144837 | KETOREDUCTASE POLYPEPTIDES FOR THE REDUCTION OF ACETOPHENONES | 05-16-2019 |